Many medications prescribed for chronic diseases come with a hidden risk: they can impair the body’s natural ability to heal wounds or even trigger the formation of skin ulcers. This side effect is often overlooked until a patient presents with a non-healing wound that complicates their primary condition. For healthcare providers, understanding which drugs are associated with these effects—and the biological mechanisms behind them—is essential for minimizing harm, adjusting therapy, and implementing early preventive wound care. This article provides a detailed, evidence-based overview of drugs known to cause skin ulcers and impair wound healing, covering pathophysiology, clinical management, and prevention strategies.

Drug Classes Implicated in Skin Ulcers and Poor Wound Healing

A broad range of pharmacologic agents can interfere with cutaneous repair. The most extensively studied include nonsteroidal anti-inflammatory drugs, corticosteroids, chemotherapeutic agents, immunosuppressants, and anticoagulants. Each class affects wound healing through distinct pathways.

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

NSAIDs, such as ibuprofen, naproxen, and diclofenac, are widely used for pain and inflammation. However, they inhibit cyclooxygenase (COX) enzymes, which reduces synthesis of prostaglandins. Prostaglandins are critical for the inflammatory phase of wound healing, promoting vasodilation and attracting immune cells. Chronically high or frequent NSAID use can blunt this initial inflammatory response, leading to delayed granulation tissue formation and weaker scar integrity. Patients on long-term NSAID therapy for arthritis or chronic pain should be monitored for any wounds that heal slowly.

Corticosteroids

Systemic corticosteroids (e.g., prednisone, dexamethasone) are potent anti-inflammatory agents but are notorious for impairing wound healing. They inhibit fibroblast proliferation, collagen synthesis, and angiogenesis. Topical corticosteroids, especially high-potency formulations, can cause skin atrophy and thinning, making the skin more susceptible to ulcers from minor trauma. Prolonged use, even at moderate doses, increases the risk of pressure ulcers and delayed surgical wound closure. Tapering to the lowest effective dose and using alternate-day regimens can mitigate some of these effects.

Chemotherapy Agents

Many chemotherapeutic drugs, including antimetabolites (methotrexate, 5-fluorouracil), alkylating agents (cyclophosphamide), and anthracyclines (doxorubicin), target rapidly dividing cells. This includes not only cancer cells but also the basal keratinocytes, fibroblasts, and endothelial cells essential for wound repair. These agents can cause direct skin toxicity, mucositis, and increased risk of infection. Patients undergoing chemotherapy often experience delayed wound closure after surgery or injury. A multidisciplinary approach involving oncology, dermatology, and wound care specialists is advised.

Immunosuppressants

Drugs such as cyclosporine, tacrolimus, mycophenolate mofetil, and biologics like tumor necrosis factor (TNF) inhibitors work by dampening the immune system. While effective for autoimmune diseases and transplant rejection, they reduce the inflammatory and immune responses that protect wounds from infection and drive healing. Chronic immunosuppression is associated with higher rates of chronic leg ulcers, surgical wound dehiscence, and skin infections that complicate healing.

Anticoagulants and Antiplatelet Agents

Warfarin, heparin, low-molecular-weight heparin, direct oral anticoagulants (e.g., rivaroxaban, apixaban), and antiplatelet drugs like aspirin and clopidogrel can cause or exacerbate skin ulcers through several mechanisms. Anticoagulants may lead to subcutaneous hemorrhage, hematoma formation, and tissue ischemia. In particular, warfarin can cause skin necrosis in patients with protein C deficiency. Antiplatelet agents impair platelet function, which is essential for the initial hemostatic plug and release of growth factors. While these drugs are often necessary for preventing thrombosis, their potential to impair wound healing must be balanced, especially in surgical patients or those with existing ulcers.

Antidiabetic Medications

Some antidiabetic agents, especially thiazolidinediones (e.g., pioglitazone), have been linked to increased risk of lower extremity ulcers. These drugs may cause fluid retention and peripheral edema, which compromises microcirculation and increases pressure on skin. Additionally, dipeptidyl peptidase-4 (DPP-4) inhibitors have been associated with bullous pemphigoid, a blistering skin condition that can lead to erosions and ulcers. Blood glucose control itself is a major factor in wound healing; drugs that cause hypoglycemia can also impair cell metabolism.

Other Notable Drugs

Several other classes have been reported to cause skin ulcers or impair healing: antihypertensives such as calcium channel blockers (nifedipine) can cause gingival hyperplasia but also peripheral edema and skin breakdown; antiepileptics like phenytoin may interfere with collagen cross-linking; and hormonal therapies (tamoxifen) have been associated with radiation recall dermatitis and ulceration. Topical medications, including some retinoids and keratolytics, can damage the epidermal barrier if overused.

Pathophysiology: How Drugs Disrupt Wound Healing

The wound healing cascade—hemostasis, inflammation, proliferation, and remodeling—relies on coordinated cellular and molecular events. Drugs can interrupt this process at multiple stages.

Impairment of Collagen Synthesis and Fibroblast Function

Corticosteroids and some chemotherapy agents directly inhibit fibroblast activity and reduce the production of collagen types I and III. Without adequate collagen, granulation tissue is weak, and the wound cannot contract or gain tensile strength. This leads to chronic non-healing ulcers and a higher risk of dehiscence.

Disruption of Angiogenesis

New blood vessel formation is critical for delivering oxygen, nutrients, and growth factors to the wound bed. NSAIDs, corticosteroids, and certain anti-angiogenic cancer therapies (e.g., bevacizumab) suppress vascular endothelial growth factor (VEGF) signaling. The resulting ischemia starves the healing tissue and predisposes to necrosis and ulceration.

Suppression of the Inflammatory Response

Inflammation is not just a nuisance after injury—it is a necessary phase that recruits immune cells to clear debris and release cytokines that orchestrate repair. Anti-inflammatory drugs, including NSAIDs and corticosteroids, blunt this response. While beneficial in chronic inflammatory conditions, the net effect on a fresh wound is delayed clearance of bacteria and dead tissue, prolonged foreign body reaction, and poor progression to proliferation.

Immune Modulation and Increased Infection Risk

Immunosuppressants reduce the activity of macrophages, neutrophils, and lymphocytes. These cells are essential for preventing wound infection. An infected wound fails to heal, becomes malodorous, and may deepen into an ulcer. Biofilm formation is more likely in immunocompromised patients, requiring aggressive antimicrobial therapy and debridement.

Direct Cytotoxicity and Tissue Damage

Chemotherapy agents, as well as some antiepileptics and antithyroid drugs, can be directly toxic to keratinocytes, endothelial cells, and other skin cells. Extravasation of vesicant chemotherapy drugs during infusion causes immediate tissue necrosis and ulceration. Other drugs may cause photosensitization, leading to severe sunburn-like reactions that blister and ulcerate.

Clinical Presentation and Risk Factors

Drug-induced skin ulcers often present as painful, well-defined lesions with a prolonged healing time. They may develop at sites of pressure, trauma, or previous radiation. Common locations include the lower extremities (especially the shins and ankles), sacrum, and heels. The ulcers are typically shallow at first but can deepen if the causative drug is not modified. In patients on corticosteroids, the skin may appear thin, fragile, and ecchymotic before an ulcer actually forms.

Several patient factors amplify the risk of drug-induced wound healing impairment:

  • Advanced age – older adults have thinner skin, reduced microcirculation, and often take multiple medications (polypharmacy).
  • Diabetes mellitus – already-impaired healing from microvascular disease and neuropathy is worsened by added drug burden.
  • Peripheral vascular disease – poor arterial or venous flow limits the healing capacity, making ulcers more likely.
  • Malnutrition – deficiencies in protein, vitamin C, zinc, and iron impair collagen synthesis and immune function.
  • Chronic kidney or liver disease – altered drug metabolism and accumulation increase toxicity risk.
  • Concurrent use of multiple high-risk drugs – synergistic effects (e.g., corticosteroids plus NSAIDs) compound the problem.

Clinicians should perform a thorough medication history and skin assessment in any patient presenting with a non-healing wound, especially if they are on one or more of the drug classes described above.

Preventive Strategies for At-Risk Patients

Prevention begins with risk stratification. For patients starting long-term therapy with corticosteroids, immunosuppressants, or anticoagulants, the following measures should be implemented:

  • Skin care routine – daily inspection, gentle cleansing with non-irritating products, and moisturizing to maintain barrier integrity.
  • Pressure redistribution – use of support surfaces, cushions, and frequent repositioning for those with limited mobility to prevent pressure ulcers.
  • Nutritional support – ensure adequate protein intake (1.2–1.5 g/kg/day), vitamin C (500 mg/day), zinc (15–25 mg/day), and hydration.
  • Medication review – whenever possible, use the lowest effective dose of corticosteroids, consider NSAID alternatives like acetaminophen for pain, and avoid prolonged courses of high-potency topical steroids.
  • Smoking cessation – nicotine constricts blood vessels and further impairs healing; smoking cessation counseling should be provided.
  • Blood glucose optimization – for diabetic patients, maintain HbA1c below 7–8% to reduce cellular metabolic stress.
  • Education – teach patients and caregivers to recognize early signs of skin breakdown: redness, induration, blistering, or pain at pressure sites.

Once an ulcer has developed or a wound is not healing as expected, a systematic approach is needed.

Discontinuation or Dose Adjustment

The first step is to evaluate whether the offending drug can be stopped, replaced, or reduced. This must be done in consultation with the prescribing specialist. Abrupt withdrawal of corticosteroids, for example, can cause adrenal crisis. Sometimes a change in formulation (e.g., from oral to topical steroid) or a switch to a different class (e.g., from warfarin to a direct oral anticoagulant) can reduce the risk without losing therapeutic effect.

Wound Care Principles

Standard wound management applies, but with extra vigilance for infection:

  • Cleansing – use gentle irrigation with saline or non-cytotoxic cleansers. Avoid harsh antiseptics like hydrogen peroxide that can damage granulation tissue.
  • Debridement – remove necrotic tissue and slough sharply or enzymatically. This is especially important in immunocompromised patients where biofilm may be present.
  • Moisture balance – select dressings that maintain a moist environment (hydrocolloids, alginates, foams) while managing exudate. Avoid dry or macerated wound beds.
  • Infection control – obtain wound swabs if signs of infection (redness, warmth, purulence, odor, increased pain). Use topical antimicrobials (silver, iodine, honey) or systemic antibiotics based on culture results.
  • Offloading – for lower extremity ulcers, use compressive therapy if venous etiology, and offloading devices (e.g., total contact cast, special footwear) for diabetic foot ulcers.

Advanced Therapies

In recalcitrant wounds, advanced modalities can be considered. Growth factor preparations (platelet-derived growth factor, PDGF) may stimulate healing, though they are expensive. Negative pressure wound therapy (NPWT) helps by removing exudate, reducing edema, and promoting granulation. For patients on anticoagulation, careful hemostasis during NPWT placement is required. Other options include bioengineered skin substitutes, hyperbaric oxygen therapy (for diabetic ulcers and radiation damage), and electrical stimulation. The evidence for these therapies is variable, but they may be beneficial when conventional care fails.

Monitoring for Drug Interactions

Wound care products themselves can interact with systemic medications. For example, silver dressings can cause argyria if used excessively, and iodine-based antiseptics can affect thyroid function in susceptible patients. Always check for potential interactions and adjust accordingly.

Special Populations Requiring Extra Vigilance

Patients with Diabetes

Diabetic patients already have a high risk of foot ulcers due to neuropathy and peripheral artery disease. Adding drugs that impair healing (e.g., corticosteroids for diabetic neuropathy pain, NSAIDs for arthritis) can accelerate ulcer formation. Strict glycemic control is paramount, and any new wound should be treated aggressively with offloading and infection control.

Elderly Patients

Polypharmacy is common in the elderly. They often take anticoagulants, antihypertensives, NSAIDs, and sometimes low-dose corticosteroids for inflammatory conditions. Skin fragility increases with age, making them vulnerable to pressure ulcers. A comprehensive geriatric assessment that includes a medication reconciliation and skin integrity check should be performed regularly.

Immunocompromised Patients

Transplant recipients and patients with autoimmune diseases on immunosuppressants require multidisciplinary care. Wounds in these patients often fail to show classic signs of infection due to blunted inflammation. A low threshold for culturing and early use of systemic antibiotics is warranted. In addition, sun protection is crucial to prevent photosensitivity-induced ulcers from medications like thiazides or doxycycline.

Patients Undergoing Surgery

Surgical patients on high-risk medications (especially corticosteroids, immunosuppressants, and anticoagulants) may experience delayed wound healing and increased infection rates. Preoperative optimization should include stopping or tapering high-dose corticosteroids (if possible), switching from warfarin to a shorter-acting anticoagulant perioperatively, and ensuring adequate nutritional status. Intraoperatively, careful handling of tissues and hemostasis reduces the risk of hematoma and seroma, which can become infected.

Conclusion

Drug-induced impairment of skin integrity and wound healing is a significant but often preventable aspect of pharmacotherapy. A wide range of medications—from common NSAIDs and corticosteroids to potent chemotherapeutic and immunosuppressive agents—can disrupt the complex biological processes required for repair. Clinicians must remain vigilant, perform thorough medication reconciliations, and educate patients about early signs of skin breakdown. When ulcers do occur, a systematic approach involving discontinuation or adjustment of the offending drug, meticulous wound care, and advanced therapies when necessary can improve outcomes. By integrating pharmacological awareness into routine wound assessment, healthcare providers can reduce morbidity, lower healthcare costs, and enhance quality of life for patients on chronic drug therapy.

For further reading: